Cyclic neutropenia, idiopathic neutropenia

Active Ingredient: Filgrastim

Indication for Filgrastim

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

In patients, children or adults with cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤0.5 × 109/L, and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.

For this indication, competent medicine agencies globally authorize below treatments:

5 ug/kg once a day

Route of admnistration

Subcutaneous

Defined daily dose

5 - 5 ug per kg of body weight

Dosage regimen

From 5 To 5 ug per kg of body weight once every day

Detailed description

The recommended starting dose is 0.5 MU (5 μg)/kg/day as a single dose or in divided doses.

Dose adjustments

Filgrastim should be administered daily by subcutaneous injection until the neutrophil count has reached and can be maintained at more than 1.5 × 109/L. When the response has been obtained, the minimal effective dose to maintain this level should be established. Long-term daily administration is required to maintain an adequate neutrophil count. After one to two weeks of therapy, the initial dose may be doubled or halved depending upon the patient’s response. Subsequently, the dose may be individually adjusted every 1-2 weeks to maintain the average neutrophil count between 1.5 × 109/L and 10 × 109/L. A faster schedule of dose escalation may be considered in patients presenting with severe infections. In clinical studies, 97% of patients who responded had a complete response at doses of ≤24 μg/kg/day. The long-term safety of administration of filgrastim at doses above 24 μg/kg/day) in patients with SCN has not been established.

Active ingredient

Filgrastim

Filgrastim causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.

Read more about Filgrastim

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.